忧郁症药物市场－全球产业规模、份额、趋势、机会和预测，依药物类别、疾病类型、药物类型、地区和竞争格局划分，2020-2030年预测

全球忧郁症药物市场规模预计将从2024年的184.6亿美元成长至2030年的217.9亿美元，年复合成长率为2.8%。全球忧郁症药物市场涵盖专门用于治疗重度忧郁症及相关精神健康问题的药物，这些药物主要透过调节大脑中的神经传导物质活性发挥作用。推动该市场扩张的关键因素包括：全球精神健康障碍盛行率不断上升、大众对这些疾病的认知度提高导致诊断率增加，以及药物研发的持续进步不断推出新的治疗方案。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球忧郁症药物市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依药物类别（非典型抗精神病药物、5-羟色胺-去甲肾上腺素再摄取抑制剂（SNRIs）、选择性5-羟色胺再摄取抑制剂（SSRIs）、中枢神经系统（CNS）兴奋剂、三环类抗忧郁剂、单胺氧化酶抑制剂、其他）
  • 依疾病类型分类（重度忧郁症、强迫症、广泛性焦虑症、恐慌症、其他）
  • 依药物类型（通用名药物、品牌药物）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美抗忧郁药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲抗忧郁药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区抗忧郁药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲忧郁症药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲忧郁症药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球忧郁症药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Otsuka Holdings Co., Ltd.
• Pfizer, Inc.
• Eli Lilly and Company
• AstraZeneca plc.
• Novartis AG
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc.
• Takeda Pharmaceutical Co., Ltd.
• AbbVie, Inc.
• Johnson & Johnson

第十六章：策略建议

第17章调查会社について・免责事项

The Global Depression Drugs Market will grow from USD 18.46 Billion in 2024 to USD 21.79 Billion by 2030 at a 2.8% CAGR. The global depression drugs market encompasses pharmaceutical agents specifically developed to treat major depressive disorder and related mental health conditions, functioning primarily by modulating neurotransmitter activity in the brain. Key drivers bolstering this market's expansion include the escalating global prevalence of mental health disorders, a growing public awareness of these conditions leading to increased diagnoses, and continuous advancements in pharmaceutical research and development introducing novel therapeutic options.

Key Market Drivers

The increasing prevalence of depressive disorders fundamentally propels the global depression drugs market by expanding the patient population requiring pharmacological interventions. These conditions represent a substantial portion of the global disease burden, necessitating a continuous supply of effective treatments. According to the World Health Organization, in September 2025, in their 'World Mental Health Today: Latest Data' and 'Mental Health Atlas 2024' reports, over one billion people worldwide are living with mental health disorders, with anxiety and depressive disorders collectively constituting more than two-thirds of all cases.

Key Market Challenges

A significant challenge impeding the sustained growth of the global depression drugs market is the limited accessibility of mental healthcare services and essential medications, particularly within emerging economies. These regions frequently contend with inadequate healthcare infrastructure and insufficient numbers of mental health professionals. This accessibility gap directly restricts patient reach and the uptake of necessary pharmacological interventions, thereby hindering overall market expansion.

Key Market Trends

The emergence of psychedelic-assisted treatment modalities represents a significant shift in the therapeutic landscape for depression, offering novel mechanisms of action beyond conventional monoaminergic approaches. These therapies, often involving compounds like psilocybin and lysergic acid diethylamide (LSD) alongside psychological support, are demonstrating promising efficacy, particularly for treatment-resistant depression. For instance, Compass Pathways announced in June 2025 that its COMP360 psilocybin achieved the primary endpoint in a Phase 3 trial for treatment-resistant depression, showing a highly statistically significant and clinically meaningful reduction in depressive symptoms after six weeks.

Key Market Players

• Otsuka Holdings Co., Ltd.
• Pfizer, Inc.
• Eli Lilly and Company
• AstraZeneca plc.
• Novartis AG
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc.
• Takeda Pharmaceutical Co., Ltd.
• AbbVie, Inc.
• Johnson & Johnson

Report Scope:

In this report, the Global Depression Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Depression Drugs Market, By Drug Class:

• Atypical Antipsychotics
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Central Nervous System (CNS) Stimulants
• Tricyclic Antidepressants
• Monoamine Oxidase Inhibitors
• Others

Depression Drugs Market, By Disorder Type:

• Major Depressive Disorder
• Obsessive-Compulsive Disorder
• Generalized Anxiety Disorder
• Panic Disorder
• Others

Depression Drugs Market, By Drug Type:

• Generic Drugs
• Branded Drugs

Depression Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Depression Drugs Market.

Available Customizations:

Global Depression Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Depression Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Selective Serotonin Reuptake Inhibitors (SSRIs), Central Nervous System (CNS) Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, Others)
  • 5.2.2. By Disorder Type (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder, Others)
  • 5.2.3. By Drug Type (Generic Drugs, Branded Drugs)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Depression Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Disorder Type
  • 6.2.3. By Drug Type
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Depression Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Disorder Type
      • 6.3.1.2.3. By Drug Type
  • 6.3.2. Canada Depression Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Disorder Type
      • 6.3.2.2.3. By Drug Type
  • 6.3.3. Mexico Depression Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Disorder Type
      • 6.3.3.2.3. By Drug Type

7. Europe Depression Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Disorder Type
  • 7.2.3. By Drug Type
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Depression Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Disorder Type
      • 7.3.1.2.3. By Drug Type
  • 7.3.2. France Depression Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Disorder Type
      • 7.3.2.2.3. By Drug Type
  • 7.3.3. United Kingdom Depression Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Disorder Type
      • 7.3.3.2.3. By Drug Type
  • 7.3.4. Italy Depression Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Disorder Type
      • 7.3.4.2.3. By Drug Type
  • 7.3.5. Spain Depression Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Disorder Type
      • 7.3.5.2.3. By Drug Type

8. Asia Pacific Depression Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Disorder Type
  • 8.2.3. By Drug Type
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Depression Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Disorder Type
      • 8.3.1.2.3. By Drug Type
  • 8.3.2. India Depression Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Disorder Type
      • 8.3.2.2.3. By Drug Type
  • 8.3.3. Japan Depression Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Disorder Type
      • 8.3.3.2.3. By Drug Type
  • 8.3.4. South Korea Depression Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Disorder Type
      • 8.3.4.2.3. By Drug Type
  • 8.3.5. Australia Depression Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Disorder Type
      • 8.3.5.2.3. By Drug Type

9. Middle East & Africa Depression Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Disorder Type
  • 9.2.3. By Drug Type
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Depression Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Disorder Type
      • 9.3.1.2.3. By Drug Type
  • 9.3.2. UAE Depression Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Disorder Type
      • 9.3.2.2.3. By Drug Type
  • 9.3.3. South Africa Depression Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Disorder Type
      • 9.3.3.2.3. By Drug Type

10. South America Depression Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Disorder Type
  • 10.2.3. By Drug Type
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Depression Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Disorder Type
      • 10.3.1.2.3. By Drug Type
  • 10.3.2. Colombia Depression Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Disorder Type
      • 10.3.2.2.3. By Drug Type
  • 10.3.3. Argentina Depression Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Disorder Type
      • 10.3.3.2.3. By Drug Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Depression Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Otsuka Holdings Co., Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer, Inc.
• 15.3. Eli Lilly and Company
• 15.4. AstraZeneca plc.
• 15.5. Novartis AG
• 15.6. Bristol-Myers Squibb Company
• 15.7. GlaxoSmithKline plc.
• 15.8. Takeda Pharmaceutical Co., Ltd.
• 15.9. AbbVie, Inc.
• 15.10. Johnson & Johnson

16. Strategic Recommendations

17. About Us & Disclaimer